Welcome to the Hope Bio Blog

As 2026 progresses, so, too, does research exploring Hope Biosciences’ proprietary cellular therapeutics in brain injury. Calendar year 2026 commenced with our cells at work in a Phase II clinical trial in Traumatic Brain Injury (TBI) executed by UTHealth Houston; early summer brought peer-reviewed publication in globe-leading neurology journal Brain of results of another TBI trial using our cells; and as summer presses on, we are delighted to begin manufacturing treatments f

By Jan Shultis During the last few weeks of 2025, Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) received Food and Drug Administration (FDA) authorization to administer Hope Biosciences’ allogeneic (donor) adipose-derived mesenchymal (adult) stem cells (HB-adMSCs) to seven men and women living with Multiple System Atrophy (MSA). As HBRF shared in their announcement, the occasion is noteworthy both for authorization of research in a rar

FOR IMMEDIATE RELEASE By Jan Shultis Sugar Land, Texas, 3 February 2026 - A multicenter trial stretching across the southwestern United States is now recruiting patients to investigate whether allogeneic (donor-derived) Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) can prevent progression of trauma-induced Acute Kidney Injury (AKI), an abrupt decline in renal function that occurs over hours to days in up to 50% of trauma and burn patients and has few eff